Cargando…
Towards Preclinical Validation of Arbaclofen (R-baclofen) Treatment for 16p11.2 Deletion Syndrome
A microdeletion on human chromosome 16p11.2 is one of the most common copy number variants associated with autism spectrum disorder and other neurodevelopmental disabilities. Arbaclofen, a GABA(B) receptor agonist, is a component of racemic baclofen, which is FDA-approved for treating spasticity, an...
Autores principales: | Gundersen, Brigitta B., O’Brien, William T., Schaffler, Melanie D., Schultz, Maria N., Tsukahara, Tatsuya, Lorenzo, Sandra Martin, Nalesso, Valerie, Luo Clayton, Alice H., Abel, Ted, Crawley, Jacqueline N., Datta, Sandeep Robert, Herault, Yann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515778/ https://www.ncbi.nlm.nih.gov/pubmed/37745360 http://dx.doi.org/10.1101/2023.05.01.538987 |
Ejemplares similares
-
R-Baclofen Reverses Cognitive Deficits and Improves Social Interactions in Two Lines of 16p11.2 Deletion Mice
por: Stoppel, Laura J, et al.
Publicado: (2018) -
Targeting the RHOA pathway improves learning and memory in adult Kctd13 and 16p11.2 deletion mouse models
por: Martin Lorenzo, Sandra, et al.
Publicado: (2021) -
Arbaclofen in fragile X syndrome: results of phase 3 trials
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2017) -
A MEG Study of Acute Arbaclofen (STX-209) Administration
por: Roberts, Timothy P. L., et al.
Publicado: (2019) -
Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder
por: Frye, Richard E
Publicado: (2014)